文献速递乳腺癌放疗放疗物理与技术

机器人立体定向体部放疗辅助治疗早期乳腺癌:大型单机构研究结果

Robotic Stereotactic Body Radiation Therapy for the Adjuvant Treatment of Early-Stage Breast Cancer: Outcomes of a Large Single-Institution Study.
PubMed 文献 · Adv Radiat Oncol · 2022-12-09

回顾性分析50例接受机器人立体定向部分乳腺照射(SAPBI)的早期乳腺癌患者,方案为30 Gy分5次连续每日照射。中位随访4.68年,1例局部复发,1例≥3级晚期毒性,44例美容效果极好。作者认为这是机器人SAPBI治疗早期乳腺癌随访时间最长的最大回顾性分析。

要点

  • 50例早期乳腺癌患者接受机器人SAPBI,30 Gy分5次连续每日照射。
  • 中位随访4.68年,1例局部复发,1例≥3级晚期毒性。
  • 44例患者美容效果极好。

核心结论

  • 作者认为这是机器人SAPBI治疗早期乳腺癌随访时间最长的最大回顾性分析,结果支持该方案可获得极好的疾病控制、极好的美容效果和有限的毒性。

研究设计与样本

  • 回顾性研究,纳入50例接受诊断的早期乳腺癌患者,均符合标准APBI条件并接受肿块切除术及基准标记放置后行机器人SAPBI。
  • 处方剂量为30 Gy分5次连续每日照射,利用基准标记和呼吸追踪维持精确剂量分布。
  • 49例患者纳入疾病控制随访,中位随访4.68年;美容效果和毒性中位随访1.25年。
  • 毒性和美容效果分别采用不良事件通用术语标准5.0版和哈佛美容量表评估。

主要发现

  • 治疗时中位年龄68.5岁,中位肿瘤大小7.2 mm,60%为浸润性细胞类型,90%为雌激素受体阳性、孕激素受体阳性或两者均阳性。
  • 1例患者出现局部复发。
  • 1例患者出现≥3级晚期毒性。
  • 44例患者美容效果极好。

临床怎么用

  • 原文结论认为,对经过选择的早期乳腺癌患者采用机器人SAPBI可实现极好的疾病控制、极好的美容效果和有限的毒性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Advancements in breast radiation therapy offer innumerable benefits to patients and the health care system. Despite promising outcomes, clinicians remain hesitant about long-term side effects and disease control with accelerated partial breast radiation therapy (APBI). Herein, we review the long-term outcomes of patients with early-stage breast cancer treated with adjuvant stereotactic partial breast irradiation (SAPBI). METHODS AND MATERIALS: This retrospective study examined outcomes of patients who received diagnoses of early-stage breast cancer treated with adjuvant robotic SAPBI. All patients were eligible for standard ABPI and underwent lumpectomy, followed by fiducial placement in preparation for SAPBI. Using fiducial and respiratory tracking to maintain a precise dose distribution throughout the course of treatment, patients received 30 Gy in 5 fractions on consecutive days. Follow-up occurred at routine intervals to evaluate disease control, toxicity, and cosmesis. Toxicity and cosmesis were characterized using the Common Terminology Criteria for Adverse Events version 5.0 and Harvard Cosmesis Scale, respectively. RESULTS: Patients (N = 50) were a median age of 68.5 years at the time of treatment. The median tumor size was 7.2 mm, 60% had an invasive cell type, and 90% were estrogen receptor positive, progesterone receptor positive, or both. Patients (n = 49) were followed for a median of 4.68 years for disease control and 1.25 years for cosmesis and toxicity. One patient experienced local recurrence, 1 patient experienced grade 3+ late toxicity, and 44 patients demonstrated excellent cosmesis. CONCLUSIONS: To our knowledge, this is the largest retrospective analysis with the longest follow-up time for disease control among patients with early breast cancer treated with robotic SAPBI. With follow-up time for cosmesis and toxicity comparable to that of previous studies, results of the present cohort advance our understanding of the excellent disease control, excellent cosmesis, and limited toxicity that can be achieved by treating select patients with early-stage breast cancer with robotic SAPBI.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jaysing A, Lischalk JW, Sanchez A, et al. Robotic Stereotactic Body Radiation Therapy for the Adjuvant Treatment of Early-Stage Breast Cancer: Outcomes of a Large Single-Institution Study. Adv Radiat Oncol. 2022. PMID: 36845620. doi:10.1016/j.adro.2022.101095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。